Cambrex (NYSE:CBM) updated its FY 2018 earnings guidance on Thursday. The company provided earnings per share (EPS) guidance of $2.95-3.09 for the period, compared to the Thomson Reuters consensus estimate of $2.79.
Several research firms have recently commented on CBM. First Analysis raised shares of Cambrex from an outperform rating to a strong-buy rating and decreased their price target for the company from $73.00 to $63.00 in a research note on Friday. Jefferies Financial Group began coverage on shares of Cambrex in a research note on Tuesday, September 25th. They set a buy rating and a $75.50 price target on the stock. Finally, Zacks Investment Research raised shares of Cambrex from a hold rating to a strong-buy rating and set a $73.00 price target on the stock in a research note on Wednesday, August 8th. Two investment analysts have rated the stock with a hold rating, two have assigned a buy rating and two have assigned a strong buy rating to the company’s stock. The company has a consensus rating of Buy and a consensus target price of $70.50.
CBM opened at $51.22 on Friday. Cambrex has a one year low of $44.80 and a one year high of $69.43. The company has a market cap of $1.88 billion, a PE ratio of 15.06, a P/E/G ratio of 2.00 and a beta of 2.42.
In other Cambrex news, CEO Steven M. Klosk sold 20,000 shares of the firm’s stock in a transaction that occurred on Tuesday, October 23rd. The shares were sold at an average price of $54.76, for a total value of $1,095,200.00. Following the transaction, the chief executive officer now directly owns 103,328 shares of the company’s stock, valued at $5,658,241.28. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CEO Steven M. Klosk sold 55,000 shares of the firm’s stock in a transaction that occurred on Tuesday, September 4th. The shares were sold at an average price of $66.30, for a total transaction of $3,646,500.00. Following the completion of the transaction, the chief executive officer now directly owns 138,328 shares in the company, valued at $9,171,146.40. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 84,510 shares of company stock worth $5,344,824. Insiders own 2.42% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: “Cambrex (CBM) Releases FY 2018 Earnings Guidance” was reported by Week Herald and is the property of of Week Herald. If you are reading this piece of content on another site, it was copied illegally and republished in violation of US & international copyright and trademark laws. The correct version of this piece of content can be viewed at https://weekherald.com/2018/11/10/cambrex-cbm-releases-fy-2018-earnings-guidance.html.
Cambrex Company Profile
Cambrex Corporation, a life sciences company, provides various products and services for the development and commercialization of new and generic therapeutics worldwide. Its products comprise active pharmaceutical ingredients and pharmaceutical intermediates that are used in the production of prescription and over-the-counter drug products, as well as other fine chemicals.
Read More: How is inflation measured?
Receive News & Ratings for Cambrex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cambrex and related companies with MarketBeat.com's FREE daily email newsletter.